Newsbenzinga
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
· Published
Article summary
Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.
An excerpt from the original article.
Comments —
Loading comments…